![ECMO Machines Market by Product [ECMO Machines, Components (Oxygenators, Pumps, Controllers)], Modality (Venovenous and Arteriovenous ECMO), Patient Type (Adults, Neonates), Application (Respiratory, Cardiac), End User (Hospitals) - Global Forecast to 2030- Product Image](http://www.researchandmarkets.com/product_images/11793/11793462_500px_jpg/ecmo_machines_market.jpg)
The ECMO machines market is projected to reach USD 0.86 billion by 2030 from USD 0.65 billion in 2025, at a CAGR of 5.8% during the forecast period.
In recent years, ECMO machines have evolved from bulky, manual-intensive systems to compact, automated, and highly efficient platforms. Next-generation ECMO integrates real-time monitoring, automated flow adjustments, and artificial intelligence (AI)-driven oxygenation control to reduce the need for constant manual intervention. Companies such as Getinge AB and Medtronic are leading in portable ECMO innovations, enabling smoother inter-hospital and intra-hospital patient transfers.
Some systems now feature wireless connectivity and cloud-based monitoring, allowing specialists to track remote patient data. Improved centrifugal pumps and polymethyl pentene (PMP) oxygenators enhance durability and reduce complications such as hemolysis or clot formation. Moreover, innovations in anticoagulation management reduce the risks of bleeding, a historical challenge for ECMO patients. These technological leaps improve patient survival and make ECMO more user-friendly for hospitals with limited staff, driving wider adoption across developed and emerging healthcare markets.
Based on product, the market of ECMO machines is divided into components and ECMO machines. In 2024, the components segment held the largest share of the global ECMO machines market. With the rising incidence of acute respiratory distress syndrome (ARDS), cardiac arrest, and multi-organ failure, ECMO usage has expanded globally across tertiary hospitals.
Each ECMO procedure consumes oxygenators, pumps, tubing sets, controllers, and cannulas. Even in short-term ECMO, components like oxygenators and cannulas are single-use, while pumps require precise compatibility and often get upgraded with each procedure. Post-pandemic preparedness further contributes to higher ECMO use, ensuring steady turnover of components. Unlike the machine itself, which remains constant, the increasing number of procedures fuels exponential growth in the component segment.
Based on patient type, the ECMO market has been categorized into adults, pediatrics and neonates. In 2024, adults held the largest market share in the ECMO machines market. The COVID-19 pandemic highlighted ECMO’s role in treating severe respiratory failure in adults. During the peak, most ECMO-supported cases were adults with severe ARDS. Even after the acute pandemic phase, many survivors experienced long-term pulmonary damage, fibrosis, and other respiratory complications that increased ECMO utilization in critical cases. Post-COVID-19 complications like myocarditis and post-viral pneumonia also primarily affect adults, contributing to higher demand for ECMO in this age group. Hospitals worldwide expanded ECMO infrastructure during the pandemic, with a focus on adult ICUs, leaving a long-term impact on equipment adoption. This legacy effect ensured that adults continued to account for the largest ECMO market share in 2024.
North America is expected to account for the largest share of the ECMO machines market during the forecast period. North America, particularly the US and Canada, benefits from a highly advanced healthcare ecosystem equipped with top-tier hospitals, critical care units, and specialized medical centers. These facilities can support sophisticated and resource-intensive technologies such as ECMO. Large tertiary hospitals and academic medical centers often serve as hubs for ECMO procedures, offering advanced ICUs and trained multidisciplinary teams that ensure effective patient management.
In contrast to emerging regions, North American hospitals possess the financial and infrastructural capacity to invest in expensive ECMO equipment and maintain it efficiently. Furthermore, strong integration of digital health systems, including advanced monitoring tools, ensures safe ECMO management. This infrastructure readiness makes it feasible for ECMO adoption at scale, enhancing accessibility and increasing survival outcomes. As a result, the well-developed healthcare network plays a central role in reinforcing North America’s leadership in the ECMO machines market.
In recent years, ECMO machines have evolved from bulky, manual-intensive systems to compact, automated, and highly efficient platforms. Next-generation ECMO integrates real-time monitoring, automated flow adjustments, and artificial intelligence (AI)-driven oxygenation control to reduce the need for constant manual intervention. Companies such as Getinge AB and Medtronic are leading in portable ECMO innovations, enabling smoother inter-hospital and intra-hospital patient transfers.
Some systems now feature wireless connectivity and cloud-based monitoring, allowing specialists to track remote patient data. Improved centrifugal pumps and polymethyl pentene (PMP) oxygenators enhance durability and reduce complications such as hemolysis or clot formation. Moreover, innovations in anticoagulation management reduce the risks of bleeding, a historical challenge for ECMO patients. These technological leaps improve patient survival and make ECMO more user-friendly for hospitals with limited staff, driving wider adoption across developed and emerging healthcare markets.
Based on product, the market of ECMO machines is divided into components and ECMO machines. In 2024, the components segment held the largest share of the global ECMO machines market. With the rising incidence of acute respiratory distress syndrome (ARDS), cardiac arrest, and multi-organ failure, ECMO usage has expanded globally across tertiary hospitals.
Each ECMO procedure consumes oxygenators, pumps, tubing sets, controllers, and cannulas. Even in short-term ECMO, components like oxygenators and cannulas are single-use, while pumps require precise compatibility and often get upgraded with each procedure. Post-pandemic preparedness further contributes to higher ECMO use, ensuring steady turnover of components. Unlike the machine itself, which remains constant, the increasing number of procedures fuels exponential growth in the component segment.
Based on patient type, the ECMO market has been categorized into adults, pediatrics and neonates. In 2024, adults held the largest market share in the ECMO machines market. The COVID-19 pandemic highlighted ECMO’s role in treating severe respiratory failure in adults. During the peak, most ECMO-supported cases were adults with severe ARDS. Even after the acute pandemic phase, many survivors experienced long-term pulmonary damage, fibrosis, and other respiratory complications that increased ECMO utilization in critical cases. Post-COVID-19 complications like myocarditis and post-viral pneumonia also primarily affect adults, contributing to higher demand for ECMO in this age group. Hospitals worldwide expanded ECMO infrastructure during the pandemic, with a focus on adult ICUs, leaving a long-term impact on equipment adoption. This legacy effect ensured that adults continued to account for the largest ECMO market share in 2024.
North America is expected to account for the largest share of the ECMO machines market during the forecast period. North America, particularly the US and Canada, benefits from a highly advanced healthcare ecosystem equipped with top-tier hospitals, critical care units, and specialized medical centers. These facilities can support sophisticated and resource-intensive technologies such as ECMO. Large tertiary hospitals and academic medical centers often serve as hubs for ECMO procedures, offering advanced ICUs and trained multidisciplinary teams that ensure effective patient management.
In contrast to emerging regions, North American hospitals possess the financial and infrastructural capacity to invest in expensive ECMO equipment and maintain it efficiently. Furthermore, strong integration of digital health systems, including advanced monitoring tools, ensures safe ECMO management. This infrastructure readiness makes it feasible for ECMO adoption at scale, enhancing accessibility and increasing survival outcomes. As a result, the well-developed healthcare network plays a central role in reinforcing North America’s leadership in the ECMO machines market.
A breakdown of the primary participants (supply-side) for the ECMO machines market referred to in this report is provided below:
- By Company Type: Tier 1: 34%, Tier 2: 38%, and Tier 3: 28%
- By Designation: C Level: 26%, Director Level: 35%, and Others: 39%
- By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%
Research Coverage
The report evaluates the ECMO machines market and estimates the market size and future growth potential based on various segments, including product, modality, patient type, application, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.Reasons to Buy the Report
The report will assist the market leader/new entrants with data on the nearest approximations of the revenue numbers for the overall ECMO machines market and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights into better positioning their businesses and making appropriate go-to-market strategies. The report assists the stakeholders in understanding the market pulse and gives them data on influential drivers, hindrances, obstacles, and opportunities in the market.This report provides insights into the following points:
- Analysis of key drivers (Increasing prevalence of cardiovascular and respiratory diseases, Growing adoption of ECMO in lung transplantation procedures), restraints (Complications associated with ECMO, High cost of ECMO procedures), opportunities (Increasing survival rates with ECMO), and challenges (Shortage of skilled professionals, Eligibility issues for ECMO)
- Product Launches/Innovations: Comprehensive details about product launches and anticipated trends in the global ECMO machines market
- Market Development: Thorough knowledge and analysis of the profitable rising markets by product, modality, patient type, application, end user, and region
- Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global ECMO machines market
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global ECMO machines market
Table of Contents
1 Introduction
2 Research Methodology
4 Premium Insights
5 Market Overview
6 Ecmo Machines Market, by Product
7 Ecmo Machines Market, by Modality
8 Ecmo Machines Market, by Patient Type
9 Ecmo Machines Market, by Application
10 Ecmo Machines Market, by End-user
11 Ecmo Machines Market, by Region
12 Competitive Landscape
13 Company Profiles
14 Appendix
List of Tables
List of Figures
Companies Mentioned
- Getinge
- Medtronic
- Terumo Corporation
- Fresenius Medical Care AG
- Livanova PLC
- Nipro
- Weigao Group Co. Ltd.
- Abbott
- Microport Scientific Corporation
- Eurosets
- Spectrum Medical
- Senko Medical Instrument Mfg. Co. Ltd.
- Chalice Medical Ltd.
- Magassist Co. Ltd.
- Braile Biomédica
- Gizmomed Private Limited
- Origen Biomedical, Inc.
- Abiomed
- Andocor
- Jiangsu Stmed Technology Co. Ltd.
- Cardioquip
- Cbm Lifemotion
- Changzhou Kangxin Medical Instruments
- Gentherm
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 252 |
| Published | October 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 0.65 Billion |
| Forecasted Market Value ( USD | $ 0.86 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
